Trials / Terminated
TerminatedNCT03515824
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of MK-1697. There are 2 parts in this study: dose escalation to determine the recommended phase 2 dose (RP2D) and confirm the RP2D (Part A) and cohort expansion to determine preliminary efficacy in participants with colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC) (Part B). No formal hypothesis testing will be done in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-1697 | Administered by IV infusion on Day 1 of each 21-day cycle |
Timeline
- Start date
- 2018-08-13
- Primary completion
- 2020-02-18
- Completion
- 2020-02-18
- First posted
- 2018-05-04
- Last updated
- 2021-03-09
- Results posted
- 2021-02-12
Locations
2 sites across 2 countries: Australia, Hong Kong
Source: ClinicalTrials.gov record NCT03515824. Inclusion in this directory is not an endorsement.